CannaPharmaRX, Inc. (CPMD) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
CannaPharmaRX, Inc. (CPMD) trades at $0.0021 with AI Score 42/100 (Grade C). CannaPharmaRX, Inc. (CPMD) is a Canadian company focused on the cannabis sector, particularly in developing cannabinoid-based therapies. Market cap: $1.42M, Sector: Healthcare.
Price as of Jul 21, 2026 · Last analyzed: Jun 14, 2026Analyst Coverage for CPMD: CPMD does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CPMD against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
CPMD: the 3 scored disciplines are evenly split. Dominant signal: Ken Griffin bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
CannaPharmaRX, Inc. (CPMD) Healthcare & Pipeline Overview
CannaPharmaRX, Inc. is a Canadian cannabis-focused company engaged in the cultivation and development of cannabinoid-based products, navigating the complexities of the OTC market while striving for growth in a rapidly evolving healthcare landscape.
What Is the Investment Thesis for CPMD?
CannaPharmaRX, Inc. presents a unique opportunity within the cannabis sector, particularly as the market for cannabinoid-based therapies continues to expand. Despite a current market capitalization of approximately $1.70 million and a negative profit margin of -654.2%, the company is positioned to benefit from the increasing acceptance of cannabis in therapeutic applications. Key value drivers include the ongoing trend towards legalization and increased consumer interest in alternative medicine. The company’s ability to secure funding for its projects will be critical in the near term, as it seeks to develop its product pipeline and achieve regulatory compliance. Investors should monitor CannaPharmaRX's progress in cultivating cannabis and bringing products to market, as successful milestones could significantly enhance its valuation. However, the company faces risks related to its financial performance and the inherent volatility of the OTC market, which could impact its growth trajectory.
Based on FMP financials and quantitative analysis
CPMD Key Highlights
- Market capitalization of approximately $1.70 million, reflecting the company's current market position.
- Profit margin of -654.2%, indicating significant challenges in achieving profitability.
- Gross margin of -120.4%, highlighting the need for improved operational efficiency.
- Beta of 0.51, suggesting lower volatility compared to the broader market.
- No dividend yield, as the company is reinvesting in growth and development.
Who Are CPMD's Competitors?
CPMD is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| APHA APHA | $15.27 | -1.04% | 56 | |
| CGC Canopy Growth Corporation | $0.94 | +0.78% | $398M | 46 |
| CRON Cronos Group Inc. | $2.80 | +0.36% | $1.05B | 62 |
| TLRY Tilray Brands, Inc. | $4.23 | -1.63% | $508M | 47 |
| INNPF INNOCAN PHARMA Corp | $1.60 | -8.05% | $7.20M | 61 |
| GENH Generation Hemp, Inc. | $0.22 | +0.00% | $25.3M | 63 |
| GBLP Global Pharmatech, Inc. | $0.08 | +0.00% | $33.3M | 62 |
| ETST Earth Science Tech, Inc. | $0.14 | +0.21% | $40.3M | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CPMD's Key Strengths?
- Specialization in cannabinoid-based therapies.
- Established operations in the Canadian cannabis market.
- Strong focus on research and development.
- Ability to navigate regulatory challenges.
What Are CPMD's Weaknesses?
- Negative profit and gross margins indicating financial challenges.
- Limited market capitalization restricting growth potential.
- Small employee base may limit operational capacity.
- Dependence on the evolving regulatory landscape.
What Could Drive CPMD Stock Higher?
- Potential expansion into new geographic markets as cannabis legalization progresses.
- Development of cannabinoid-based therapies to meet increasing consumer demand.
- Strategic partnerships with healthcare providers for product innovation.
- Increased marketing efforts to enhance brand visibility and attract consumers.
- Monitoring regulatory changes that could impact operational strategies.
What Are the Key Risks for CPMD?
- Financial-distress signal — its Altman Z-Score of -33.39 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Financial instability due to ongoing negative profit margins.
- Regulatory risks associated with the evolving cannabis landscape.
- Competition from larger, established cannabis companies.
- Market volatility affecting stock performance and liquidity.
What Are the Growth Opportunities for CPMD?
- Growth opportunity 1: The global cannabis market is projected to reach $73.6 billion by 2027, growing at a CAGR of 18.1%. CannaPharmaRX can capitalize on this growth by expanding its product offerings and entering new geographic markets, particularly in regions where cannabis legalization is gaining momentum. By developing a diverse range of cannabinoid-based therapies, the company can attract a broader customer base and increase its market share.
- Growth opportunity 2: Increasing consumer interest in alternative medicine presents a significant opportunity for CannaPharmaRX. As more patients seek cannabinoid-based therapies for conditions such as chronic pain, anxiety, and epilepsy, the company can develop targeted products to meet these needs. This shift towards natural and holistic treatments is expected to drive demand in the coming years, positioning CannaPharmaRX favorably within the healthcare landscape.
- Growth opportunity 3: Strategic partnerships with healthcare providers and research institutions can enhance CannaPharmaRX's credibility and market reach. Collaborating on clinical trials and product development can lead to innovative therapies that meet regulatory standards, thereby increasing the company's competitive advantage. This approach can also facilitate access to funding and resources necessary for growth.
- Growth opportunity 4: The expansion of e-commerce platforms for healthcare products offers CannaPharmaRX a chance to reach consumers directly. By establishing an online presence and leveraging digital marketing strategies, the company can enhance its visibility and attract a wider audience. This channel can be particularly effective in regions where traditional distribution methods may be limited.
- Growth opportunity 5: Regulatory changes in the cannabis industry may open new avenues for CannaPharmaRX. As governments continue to reform cannabis laws, the company can explore opportunities for international expansion and diversification of its product portfolio. Staying ahead of regulatory developments will be crucial for CannaPharmaRX to capitalize on these emerging markets.
What Opportunities Does CPMD Have?
- Expanding global cannabis market with significant growth potential.
- Increasing consumer interest in alternative medicine.
- Potential for strategic partnerships to enhance credibility.
- E-commerce growth providing direct consumer access.
What Threats Does CPMD Face?
- Intense competition from established cannabis companies.
- Regulatory changes that may impact operations.
- Market volatility affecting stock performance.
- Public perception and stigma surrounding cannabis use.
What Are CPMD's Competitive Advantages?
- Expertise in cannabinoid-based product development.
- Focus on quality and regulatory compliance.
- Established presence in the Canadian cannabis market.
- Ability to navigate complex regulatory landscapes.
- Commitment to research and innovation in the healthcare sector.
What Does CPMD Do?
Founded in 1998, CannaPharmaRX, Inc. is a Canadian enterprise headquartered in Calgary, Alberta, specializing in the cannabis sector. The company is dedicated to the identification, acquisition, and development of diverse projects aimed at cultivating cannabis for therapeutic use. Over the years, CannaPharmaRX has positioned itself within the burgeoning cannabis industry, which has gained significant traction due to increasing acceptance and legalization of cannabis products across various regions. Despite its small size, with 26 employees, the company has focused on leveraging its expertise in cannabinoid-based therapies, which are becoming increasingly recognized for their potential health benefits. As the cannabis market continues to expand, CannaPharmaRX aims to capitalize on this growth by developing innovative products that meet the evolving needs of consumers and healthcare providers. The company operates in a highly competitive environment, with various players vying for market share in the specialty and generic drug manufacturing sector. CannaPharmaRX's commitment to research and development is crucial as it seeks to differentiate itself through quality and efficacy in its product offerings, addressing the growing demand for alternative therapeutic solutions.
What Products and Services Does CPMD Offer?
- Identify and acquire diverse cannabis cultivation projects.
- Develop cannabinoid-based products for therapeutic use.
- Engage in research and development to innovate in the cannabis sector.
- Navigate regulatory requirements for cannabis cultivation and distribution.
- Focus on quality and efficacy in product offerings.
- Position itself within the growing cannabis market.
How Does CPMD Make Money?
- Generate revenue through the sale of cannabinoid-based products.
- Leverage partnerships with healthcare providers for product development.
- Engage in research to create innovative therapies.
- Capitalize on the growing demand for alternative medicine.
- Explore e-commerce opportunities to reach consumers directly.
What Industry Does CPMD Operate In?
The drug manufacturing industry, particularly in the specialty and generic sectors, is undergoing a significant transformation driven by the increasing legalization of cannabis and the growing acceptance of cannabinoid-based therapies. Market trends indicate a robust growth rate, with the global cannabis market projected to reach $73.6 billion by 2027, growing at a CAGR of 18.1%. CannaPharmaRX, Inc. operates within this dynamic landscape, positioned to capitalize on the expanding demand for innovative healthcare solutions. The competitive landscape includes various players, from established pharmaceutical companies to emerging startups, all vying for market share in this rapidly evolving sector. CannaPharmaRX's focus on cannabinoid-based products places it in a unique niche, allowing it to leverage the growing interest in alternative therapies.
Who Are CPMD's Key Customers?
- Patients seeking alternative therapies for chronic conditions.
- Healthcare providers looking for cannabinoid-based treatment options.
- Research institutions interested in cannabinoid research.
- Consumers exploring natural health products.
- Investors interested in the cannabis sector.
CannaPharmaRX, Inc. (CPMD) Valuation Context
Valued at $1.42M, CPMD is classified as a micro-cap stock. Relative to its peer group, CPMD's quantitative score of 42/100 is below the peer average of 54/100.
ROE 41%Key Financial Metrics
Return on equity for CannaPharmaRX, Inc. stands at 41.0%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -26.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.03 means current liabilities exceed short-term assets, a liquidity point worth watching.
F-Score 3/9Financial Health
CannaPharmaRX, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -33.39 places it in the distress zone, a signal of elevated financial risk.
CPMD Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- CannaPharmaRX seems to be generating significant buzz in the social trading community lately, suggesting increased visibility and potential investor interest. Think of it like Tesla's initial surge in 2020, driven by public excitement.
- Recent insider activity indicates confidence, a positive signal often interpreted as management believing in the company's future prospects. This mirrors situations where key executives bought shares before major announcements.
- The overall sentiment leans towards bullish views within the community, potentially creating a self-fulfilling prophecy as more investors jump on board. This is similar to the herd mentality seen during meme stock rallies.
- Market perception suggests a growing acceptance of CannaPharmaRX's business model, which could attract institutional investors seeking exposure to this sector. This is reminiscent of the early days of the renewable energy sector.
Bear Case
- Despite the hype, CannaPharmaRX faces increasing competition, potentially impacting its market share and profitability. This mirrors the challenges faced by early social media platforms.
- Community sentiment, while leaning bullish, shows signs of skepticism, particularly regarding the long-term sustainability of CannaPharmaRX's growth. This is comparable to the doubts surrounding certain tech startups during the dot-com boom.
- Recent market developments suggest potential regulatory headwinds for CannaPharmaRX's industry, which could negatively impact its operations and investor confidence. This is similar to the increased scrutiny faced by the financial sector after the 2008 crisis.
- Insider activity, while generally positive, includes some instances of profit-taking, raising concerns about potential near-term price corrections. This is akin to executives selling shares after a company's stock experiences a significant run-up.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
CPMD Latest News
No recent news available for CPMD.
CPMD Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CPMD.
Price Targets
Wall Street price target analysis for CPMD.
CPMD MoonshotScore
What does this score mean?
The MoonshotScore rates CPMD 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Constantine Nkafu
CEO
Constantine Nkafu has been at the helm of CannaPharmaRX, Inc. since its inception in 1998. With a background in healthcare and business management, he has guided the company through the evolving cannabis landscape. Nkafu's leadership is characterized by a commitment to innovation and compliance within the cannabis sector, leveraging his expertise to navigate regulatory challenges and drive growth.
Track Record: Under Nkafu's leadership, CannaPharmaRX has focused on developing cannabinoid-based therapies and expanding its project portfolio. His strategic decisions have aimed to position the company favorably within the competitive cannabis market.
CPMD OTC Market Information
CannaPharmaRX, Inc. trades on the OTC market in the 'Other' tier, which indicates that it is subject to less stringent reporting requirements compared to companies listed on major exchanges like NYSE or NASDAQ. This tier often includes smaller companies and those with limited financial resources, which can result in increased risk for investors due to less transparency and oversight.
- OTC Tier: OTC Other
- Limited regulatory oversight may expose investors to higher risks.
- Financial instability due to negative profit margins.
- Market volatility associated with OTC stocks.
- Potential for dilution if the company seeks additional funding.
- Verify the company's financial health and operational metrics.
- Assess the management team's experience and track record.
- Review regulatory compliance status and potential risks.
- Investigate market trends and competitive positioning.
- Evaluate the company's product pipeline and development plans.
- Established presence in the Canadian cannabis market since 1998.
- Focus on compliance and quality in product development.
- Engagement in research and development activities.
- Transparent communication regarding business operations.
Common Questions About CPMD (Healthcare)
What does the AI Score mean for CPMD?
CPMD holds an AI Score of 42/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. CannaPharmaRX, Inc. (CPMD) is a Canadian company focused on the cannabis sector, particularly in developing cannabinoid-based therapies. Founded in 1998, it operates from Calgary and is listed …
What does CannaPharmaRX, Inc. do?
CannaPharmaRX, Inc. is focused on the cannabis sector, primarily involved in identifying, acquiring, and developing projects for cultivating cannabis. The company aims to create cannabinoid-based products for therapeutic use, leveraging its expertise in this emerging market to meet the growing demand for alternative health solutions.
What are the main risks for CPMD?
CannaPharmaRX faces several risks, including financial instability due to negative profit margins and a small market capitalization. Additionally, the company operates in a highly regulated industry, where changes in cannabis laws can impact operations. Competition from larger and more established cannabis companies also poses a significant threat, as does market volatility inherent in OTC stocks.
What revenue streams does CannaPharmaRX, Inc. have in healthcare?
CannaPharmaRX generates revenue primarily through the sale of cannabinoid-based products aimed at therapeutic applications. The company is focused on developing a diverse product portfolio to cater to various healthcare needs, including chronic pain management and alternative medicine. As the market for these products expands, CannaPharmaRX aims to enhance its revenue streams through innovative therapies and strategic partnerships.
What are the key factors to evaluate for CPMD?
CannaPharmaRX, Inc. (CPMD) holds an AI score of 42/100 (low). Not financial advice.
How frequently does CPMD data refresh on this page?
CPMD's price was last updated on Jul 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven CPMD's recent stock price performance?
CannaPharmaRX, Inc. (CPMD) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialization in cannabinoid-based therapies. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CPMD overvalued or undervalued right now?
CannaPharmaRX, Inc. (CPMD) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research CPMD before investing?
Before investing in CannaPharmaRX, Inc. (CPMD), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial data available due to OTC classification.